Clinical trials: Fat Disorder
Scleroderma
Scleroderma Treatment With Celution Processed ADRCs Registry
This registry study will assess the safety and performance of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand scleroderma.
- Trial name
- STAR (NCT02328625)
- Sponsor
- Cytori Therapeutics
Hypercholesterolemia
LIP-01 in Hypercholesterolemia
The purpose of this study is to determine a safe and tolerable dose of LIP-01
- Trial name
- NCT00966225
- Testing
- LIP-01
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Familial Hypercholesterolemia
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind…
- Trial name
- NCT00355615
- Testing
- Rosuvastatin
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- AstraZeneca
Fabry Disease
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
GR181413A/AT1001 (migalastat hydrochloride) is a low molecular weight iminosugar, an analog of the terminal galactose group that is cleaved from the substrate GL-3.
- Trial name
- NCT01853852
- Testing
- GR181413A/AT1001 solution, GR181413A/AT1001 capsule, Potable water
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Inflammatory Bowel Disease
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.
- Trial name
- NCT03555617
- Testing
- TD-1473, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Dyslipidemia
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
The primary objective of this study is to evaluate the efficacy of different doses of TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction…
- Trial name
- TULIP (NCT01970215)
- Testing
- TA-8995, Atorvastatin, Rosuvastatin
- Where
- 17 sites in Denmark, Netherlands
- Volunteers
- 364 people
- Sponsor
- Xention Ltd
Overweight, Obesity
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle modification…
- Conditions
- Overweight, Obesity, Overweight and Obesity, Overweight or Obesity
- Trial name
- NCT04110717
- Testing
- Vestal Device, Control Device, Hypocaloric Diet
- Where
- Ireland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Hyperlipidemias
Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337
Compare the pharmacokinetic characteristics and safety between CKD-391 tablet and D337, D337 combination
- Trial name
- NCT03793985
- Testing
- T, R
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemia, Glucose Metabolism Disorder
Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on…
- Trial name
- NCT00361868
- Testing
- fenofibrate (F) + metformin (M) hydrochloride fixed combination, Rosiglitazone
- Where
- 70 sites in Croatia, Finland and 6 more
- Volunteers
- 88 people
- Sponsor
- Solvay Pharmaceuticals
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- LFQ (NCT04657523)
- Testing
- Investigational Liver Fat Quantification Software
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Hypercholesterolemia, Dyslipidemia
Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers.
- Trial name
- NCT01163838
- Testing
- 1 mg/kg every 2 weeks, 2 mg/kg every 4 weeks, 4 mg/kg every 4 weeks
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia, Coronary Disease
The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe/simvastatin 10/20 mg when administered daily versus doubling the dose of simvastatin to 40 mg in patients with hypercholesterolemia and…
- Trial name
- NCT00423579
- Testing
- Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg
- Volunteers
- 120 people
- Sponsor
- Organon and Co
Lipoprotein Lipase Deficiency, Inborn Error of Lipid Metabolism
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Homozygous familial Hypercholesterolemia from blood
- Conditions
- Lipoprotein Lipase Deficiency, Inborn Error of Lipid Metabolism, Corneal Arcus
- Trial name
- BioHoFH (NCT03198897)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
To Determine Bioequivalence Under Fed Conditions
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent to 100 mg doxycycline (Par) versus Monodox (Oclassen Pharmaceuticals)
- Trial name
- NCT00652704
- Testing
- Doxycycline monohydrate, Monodox
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Dyslipidemias, Hypertension
To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers
To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.
- Trial name
- NCT05259020
- Testing
- ID140009, ID1803+ID1805
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Lysosomal Acid Lipase Deficiency, Wolman Disease
A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype
This is a Natural History study to characterize key aspects of the clinical course of lysosomal acid lipase (LAL) deficiency/Wolman phenotype in patients.
- Trial name
- NCT01358370
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Gaucher Disease Type I, Cerebroside Lipidosis Syndrome
A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
This is a multicenter, open-label, prospective study of the efficacy of Cerezyme in treating patients with skeletal manifestations secondary to Type I Gaucher disease.
- Conditions
- Gaucher Disease Type I, Cerebroside Lipidosis Syndrome, Clucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
- Trial name
- NCT00365131
- Testing
- Cerezyme (imiglucerase for injection)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Rheumatoid Arthritis
Outcomes Data of Adipose Stem Cells to Treat Rheumatoid Arthritis
The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on pain and functionality in people with…
- Trial name
- NCT02348086
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- StemGenex